Publication: 2929

Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: results from two prospective cohorts and CALGB 89803 (Alliance) trial
      QxMD      Google Scholar   
Citation:
Eur J Cancer vol 111 82-93
Year:
2019
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Meta-Analysis
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
8
Parents:
None
Children:
None
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
   
Pharmas:
Pfizer  
Grants:
U10CA180821, U10CA180882, U10CA180791, U10CA180867, U24CA196171, P01 CA87969, UM1 CA186107, P01 CA55075, UM1 CA167552, P50 CA127003, R01 CA118553, R01 CA169141, R01 CA137178, K24 DK098311, R01 CA205406, R35 CA197735, R01 CA151993 to S.O., K07 CA190673, K07 CA188126, SU2C-AACR-DT22-17, JP2017-775  
Corr. Author:
 
Authors:
                                                       
Networks:
LAPS-CT018, LAPS-MA036, LAPS-MN026, LAPS-NY016   
Study
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-89803
Phases:
3
Keywords:
adenocarcinoma, clinical outcome, colorectal neoplasm, immunity, immunology, inflammation, inflammatory mediator, molecular pathological epidemiology, precision medicine, prostaglandin, PTGS, RAF